Trial Profile
Double Blind Randomized Clinical Study Evaluating Efficacy and Safety of BCD-020 and MabThera in Patients With Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Other DMARDs Including One or More TNF Inhibitor Therapies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Glucocorticoids; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms BIORA
- Sponsors Biocad
- 15 Jun 2019 Results (n=54) assessing effect of Bcd-020 on Inflammatory and Immunological Biomarkers in Patients with Rheumatoid Arthritis presented at the 20th Annual Congress of the European League Against Rheumatism
- 28 Aug 2016 Status changed from active, no longer recruiting to completed according to results presented at the 17th Annual congress of the European League Against Rheumatism.
- 12 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.